Short answer
Annexon, Inc. (ANNX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). ANN-EXON’s GBS FORWARD study reported rapid positive clinical responses in all tanruprubart-treated patients within one week.
Annexon, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ANN-EXON’s GBS FORWARD study reported rapid positive clinical responses in all tanruprubart-treated patients within one week
- Results cover the first U.S. and European patient cohort, supporting early clinical activity in Guillain-Barré syndrome
- Press release details and patient data appear in Exhibit 99.1, the key source for assessing response magnitude and durability
Item EX-99.1 · Exhibit EX-99.1
- FORWARD initial cohort showed rapid strength improvement in all 10 patients within four days after one 30 mg/kg infusion
- Four bedbound patients walked by days 2–8; the sole ventilated patient discontinued ventilation within four days
- Results reinforce Phase 3 findings, where approximately 90% improved meaningfully by day 8, supporting tanruprubart’s disease-modifying potential
- Data expected to support FDA BLA submission targeted for Q4 2026; EMA marketing application remains under review
- Commercial opportunity tied to approximately 22,000 annual U.S. and European patients and over $20 billion U.S. annual healthcare burden
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Annexon, Inc. 8-K filings
Get the next ANNX 8-K as it lands
Follow ANNX for push alerts, or ask the research agent what this filing means.